FPIs pull out net Rs 476 crore so far in September from Indian markets

According to depositories data, FPIs have withdrawn a net Rs 4,016 crore from equities and invested a net sum of Rs 3,540 crore in debt instruments during September 1-25 — a net outflow of Rs 476 crore.

Foreign portfolio investors (FPI) have pulled out Rs 476 crore on net basis so far from Indian markets in September, reflecting a cautious stance by participants amid fears of resurgence of coronavirus cases in Europe and other countries.

FPIs remained net buyers for three consecutive months — June-August.

They had invested Rs 46,532 crore in August, Rs 3,301 crore in July and Rs 24,053 crore in June on net basis.

"The renewed fears of re-emergence and surge in coronavirus cases in Europe and other countries have raised concerns about the possibility of fresh lockdowns being imposed in infected regions, which would have prompted FPIs to adopt a cautious stance," said Himanshu Srivastava, associate director – manager research, Morningstar India.

Moreover, the rising COVID-19 cases in India and the challenges faced by the Indian economy do not instill confidence either, he said.

Given the surge in equity markets over the last few months and appreciation in Indian rupee against the greenback, FPIs would have found this as an opportune time to book profit ahead of impending uncertainty, Srivastava added.

Harsh Jain, co-founder and COO at Groww, said, "Due to the high liquidity thanks to printing of money, there is a lot of money flowing in the system which also results in quick ballooning of different assets. This results in quick investments and quick withdrawals from different assets. We have already seen such movements in equity, treasuries, gold, and even silver over the last few months.”

In a world with so much liquidity, such bigger-than-normal drawdowns and market climbs will happen for some more time, Jain added.

Regarding investment in debt segment, Jain said the revival of interest in debt is a fresh change that was missing for nearly six months.

Citing reasons for the investment in bonds market, Srivastava said amid aggressive bond buying by the US Federal Reserve, the yields there have come down.

This could be one of the reasons for FPIs to look for other attractive investment destinations like Indian debt markets, which could potentially offer better returns.

Commenting on future of FPI flows, Jain said that big events to look forward are US election results and US-China relations as these two factors have been a major driver behind market moves in the last year and investors would need favourable signs on both ends to be more certain of their investment plans going forward.

Source - Moneycontrol.com

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

SD Solutions

Search This Blog